| Dr Mohammad Sadi, | |
|
1500 Duarte Rd, Duarte, CA 91010-3012 | |
| (626) 256-4673 | |
| Not Available |
| Full Name | Dr Mohammad Sadi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 1500 Duarte Rd, Duarte, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932512704 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A168591 (California) | Primary |
| 208M00000X | Hospitalist | 036144040 (Illinois) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Hope Medical Foundation | 3779751656 | 686 |
News Archive
Face masks are thought to slow the spread of viruses, including the novel coronavirus that causes COVID-19, but little is known about how well they work.
One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.
What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize - or even completely replace - animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego, California (Germany Pavilion, Booth 4513-03).
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
› Verified 9 days ago
| Entity Name | City Of Hope Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871886366 PECOS PAC ID: 3779751656 Enrollment ID: O20110720000244 |
News Archive
Face masks are thought to slow the spread of viruses, including the novel coronavirus that causes COVID-19, but little is known about how well they work.
One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.
What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize - or even completely replace - animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego, California (Germany Pavilion, Booth 4513-03).
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohammad Sadi, Po Box 512185, Los Angeles, CA 90051-0185 Ph: (626) 256-4673 | Dr Mohammad Sadi, 1500 Duarte Rd, Duarte, CA 91010-3012 Ph: (626) 256-4673 |
News Archive
Face masks are thought to slow the spread of viruses, including the novel coronavirus that causes COVID-19, but little is known about how well they work.
One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.
What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize - or even completely replace - animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego, California (Germany Pavilion, Booth 4513-03).
Patients with two out of the three most common types of advanced breast cancer now have an average survival time of at least five years, according to a panel of experts at the Advanced Breast Cancer Sixth International Consensus Conference (ABC 6).
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
› Verified 9 days ago
Maria F Santander, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Ravindrakumar G Guruswamy, M. D., MPH Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 E. Duarte Road, Duarte, CA 91010 Phone: 626-256-4673 | |
Dr. Monique Kim Phan, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 E. Duarte Road, Duarte, CA 91010 Phone: 626-256-4673 | |
Wajidah Abdul-khabir, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Kourosh Golestany, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Dr. Jay I Varughese, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 Duarte Rd, Duarte, CA 91010 Phone: 626-256-4673 | |
Cornelia G. Banciu-odell, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1500 E. Duarte Road, Duarte, CA 91010 Phone: 626-256-4673 |